Targeting fibroblast growth factor receptors causes severe craniofacial malformations in zebrafish larvae

by Selleckchem | Mar 16 2023

Background and objective: A key pathway controlling skeletal development is fibroblast growth factor (FGF) and FGF receptor (FGFR) signaling. Major regulatory functions of FGF signaling are chondrogenesis, endochondral and intramembranous bone development. In this study we focus on fgfr2, as mutations in this gene are found in patients with craniofacial malformations. The high degree of conservation between FGF signaling of human and zebrafish (Danio rerio) tempted us to investigate effects of the mutated fgfr2 sa10729 allele in zebrafish on cartilage and bone formation.

Methods: We stained cartilage and bone in 5 days post fertilization (dpf) zebrafish larvae and compared mutants with wildtypes. We also determined the expression of genes related to these processes. We further investigated whether pharmacological blocking of all FGFRs with the inhibitor BGJ398, during 0-12 and 24-36 h post fertilization (hpf), affected craniofacial structure development at 5 dpf.

Results: We found only subtle differences in craniofacial morphology between wildtypes and mutants, likely because of receptor redundancy. After exposure to BGJ398, we found dose-dependent cartilage and bone malformations, with more severe defects in fish exposed during 0-12 hpf. These results suggest impairment of cranial neural crest cell survival and/or differentiation by FGFR inhibition. Compensatory reactions by upregulation of fgfr1a, fgfr1b, fgfr4, sp7 and dlx2a were found in the 0-12 hpf group, while in the 24-36 hpf group only upregulation of fgf3 was found together with downregulation of fgfr1a and fgfr2.

Conclusions: Pharmacological targeting of FGFR1-4 kinase signaling causes severe craniofacial malformations, whereas abrogation of FGFR2 kinase signaling alone does not induce craniofacial skeletal abnormalities. These findings enhance our understanding of the role of FGFRs in the etiology of craniofacial malformations.

Comments：

The study aimed to investigate the effects of mutated fgfr2 sa10729 allele in zebrafish on cartilage and bone formation. The researchers stained cartilage and bone in 5 days post-fertilization zebrafish larvae and compared mutants with wildtypes. They also determined the expression of genes related to these processes. Further, they investigated the effects of pharmacological blocking of all FGFRs with the inhibitor BGJ398 during two developmental stages on craniofacial structure development.

The researchers found only subtle differences in craniofacial morphology between wildtypes and mutants, likely because of receptor redundancy. However, exposure to BGJ398 resulted in dose-dependent cartilage and bone malformations, with more severe defects in fish exposed during 0-12 hpf. These results suggest impairment of cranial neural crest cell survival and/or differentiation by FGFR inhibition.

The study identified compensatory reactions by upregulation of fgfr1a, fgfr1b, fgfr4, sp7, and dlx2a in the 0-12 hpf group, while in the 24-36 hpf group, only upregulation of fgf3 was found together with downregulation of fgfr1a and fgfr2. The findings suggest that pharmacological targeting of FGFR1-4 kinase signaling causes severe craniofacial malformations, whereas abrogation of FGFR2 kinase signaling alone does not induce craniofacial skeletal abnormalities.

Overall, the study enhances our understanding of the role of FGFRs in the etiology of craniofacial malformations and provides insights into potential targets for therapeutic interventions.